Adagene Inc. (ADAG)
3.26
-0.06 (1.81%)
Upcoming Events
Latest Headlines
Form SCHEDULE 13D/A Adagene Inc. Filed by: Luo Peter
June 8, 2026 6:23 AM - SEC Filing
Form SCHEDULE 13G/A Adagene Inc. Filed by: WuXi PharmaTech Healthcare Fund I L.P.
May 15, 2026 4:32 PM - SEC Filing
Adagene to Participate in Two Upcoming Investor Conferences
May 12, 2026 8:30 AM - Globe NewsWire
Form SCHEDULE 13G Adagene Inc. Filed by: JANUS HENDERSON GROUP PLC
May 7, 2026 11:30 AM - SEC Filing
Adagene presents trial data showing muzastotug combination benefits
April 17, 2026 4:01 PM - StreetInsider
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types
April 17, 2026 4:01 PM - StreetInsider
Form 6-K Adagene Inc. For: Apr 17
April 17, 2026 4:00 PM - SEC Filing
Adagene adds Peter Lebowitz to scientific advisory board
April 14, 2026 7:01 AM - StreetInsider
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board
April 14, 2026 7:00 AM - Globe NewsWire
H.C. Wainwright Reiterates Buy Rating on Adagene Inc (ADAG)
April 7, 2026 7:49 AM - StreetInsider
Adagene Inc (ADAG) PT Raised to $10 at Guggenheim
April 6, 2026 6:38 AM - StreetInsider
Form 424B5 Adagene Inc.
April 2, 2026 4:26 PM - SEC Filing
Adagene Inc (ADAG) PT Raised to $8 at Leerink Partners
April 2, 2026 2:53 PM - StreetInsider
Form 6-K Adagene Inc. For: Apr 02
April 2, 2026 7:12 AM - SEC Filing
Adagene prices $70 million public offering at $3.75 per ADS
April 2, 2026 7:10 AM - StreetInsider
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs
April 2, 2026 7:10 AM - StreetInsider
Adagene partners with Incyte for cancer drug combination study
April 2, 2026 7:01 AM - StreetInsider
Form 424B5 Adagene Inc.
April 2, 2026 7:01 AM - SEC Filing
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable
April 2, 2026 7:01 AM - StreetInsider
Form 6-K Adagene Inc. For: Apr 02
April 2, 2026 7:00 AM - SEC Filing
Adagene reports higher response rates with increased muzastotug dosing
April 2, 2026 7:00 AM - StreetInsider
Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Re
April 2, 2026 7:00 AM - StreetInsider
Form 6-K Adagene Inc. For: Apr 01
April 1, 2026 5:16 PM - SEC Filing
Form 20-F Adagene Inc. For: Dec 31
April 1, 2026 5:16 PM - SEC Filing
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update
April 1, 2026 5:00 PM - StreetInsider
Form SCHEDULE 13G Adagene Inc. Filed by: Chernett Jorey
March 18, 2026 9:23 AM - SEC Filing
Form 3 Adagene Inc. For: Mar 18 Filed by: Chane-Du Mickael Yannick
March 18, 2026 9:05 AM - SEC Filing
Form 3 Adagene Inc. For: Mar 18 Filed by: Tam Man Kin
March 18, 2026 9:05 AM - SEC Filing
Form 3 Adagene Inc. For: Mar 18 Filed by: Luo Peter
March 18, 2026 9:04 AM - SEC Filing
Form 3 Adagene Inc. For: Mar 18 Filed by: Zhou Ling
March 18, 2026 9:04 AM - SEC Filing
Form 3 Adagene Inc. For: Mar 18 Filed by: Zhu Li
March 18, 2026 9:04 AM - SEC Filing
Form 3 Adagene Inc. For: Mar 18 Filed by: Cheung Andy Yiu Leung
March 18, 2026 9:03 AM - SEC Filing
Form 3 Adagene Inc. For: Mar 18 Filed by: GU CHUNFANG
March 18, 2026 9:03 AM - SEC Filing
Form 3 Adagene Inc. For: Mar 18 Filed by: Zhao Qinghai
March 18, 2026 9:02 AM - SEC Filing
Form 3 Adagene Inc. For: Mar 18 Filed by: DO CUONG V
March 18, 2026 9:02 AM - SEC Filing
Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA
March 17, 2026 4:35 PM - StreetInsider
Form 3 Adagene Inc. For: Mar 17 Filed by: Grawunder Ulf
March 17, 2026 8:56 AM - SEC Filing
CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsight
March 10, 2026 5:31 PM - PR NewsWire
Full Article List
